These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

760 related items for PubMed ID: 30116244

  • 1. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG, Testori M, Cheminay C, Volkmann A.
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [Abstract] [Full Text] [Related]

  • 2. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.
    Julander JG, Trent DW, Monath TP.
    Vaccine; 2011 Aug 11; 29(35):6008-16. PubMed ID: 21718741
    [Abstract] [Full Text] [Related]

  • 3. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
    Jiang X, Dalebout TJ, Lukashevich IS, Bredenbeek PJ, Franco D.
    J Gen Virol; 2015 Apr 11; 96(Pt 4):804-814. PubMed ID: 25516543
    [Abstract] [Full Text] [Related]

  • 4. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
    Wang HJ, Guo Y, He MJ, Liu ZY, Ye Q, Huang XY, Deng YQ, Li XF, Qin CF.
    Microbiol Spectr; 2022 Oct 26; 10(5):e0224622. PubMed ID: 35980184
    [Abstract] [Full Text] [Related]

  • 5. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanesa-Thasan N, Feroldi E, Reid M.
    Hum Vaccin; 2010 Nov 26; 6(11):906-14. PubMed ID: 20864814
    [Abstract] [Full Text] [Related]

  • 6. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR, Larsen MA, Kongsgaard M, Rasmussen M, Buus S, Stryhn A, Thomsen AR, Christensen JP.
    PLoS Negl Trop Dis; 2016 Feb 26; 10(2):e0004464. PubMed ID: 26886513
    [Abstract] [Full Text] [Related]

  • 7. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
    Ma J, Yakass MB, Jansen S, Malengier-Devlies B, Van Looveren D, Sanchez-Felipe L, Vercruysse T, Weynand B, Javarappa MPA, Quaye O, Matthys P, Roskams T, Neyts J, Thibaut HJ, Dallmeier K.
    EBioMedicine; 2022 Sep 26; 83():104240. PubMed ID: 36041265
    [Abstract] [Full Text] [Related]

  • 8. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Piras-Douce F, Raynal F, Raquin A, Girerd-Chambaz Y, Gautheron S, Sanchez MEN, Vangelisti M, Mantel N.
    Vaccine; 2021 Mar 26; 39(13):1846-1856. PubMed ID: 33685778
    [Abstract] [Full Text] [Related]

  • 9. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P.
    J Infect Dis; 2003 Oct 15; 188(8):1213-30. PubMed ID: 14551893
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
    Piras-Douce F, Broudic K, Chautard E, Raynal F, Courtois V, Gautheron S, Mantel N.
    Vaccine; 2023 Feb 17; 41(8):1457-1470. PubMed ID: 36702693
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, Bedford P, Lang J, Quentin-Millet MJ, Monath TP.
    Hum Vaccin; 2006 Feb 17; 2(2):60-7. PubMed ID: 17012873
    [Abstract] [Full Text] [Related]

  • 14. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
    Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, Levesque P, Bowick GC, Morin M, Fowler E, Trent DW.
    Vaccine; 2010 May 14; 28(22):3827-40. PubMed ID: 20347059
    [Abstract] [Full Text] [Related]

  • 15. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.
    Tottey S, Shoji Y, Jones RM, Chichester JA, Green BJ, Musiychuk K, Si H, Manceva SD, Rhee A, Shamloul M, Norikane J, Guimarães RC, Caride E, Silva ANMR, Simões M, Neves PCC, Marchevsky R, Freire MS, Streatfield SJ, Yusibov V.
    Am J Trop Med Hyg; 2018 Feb 14; 98(2):420-431. PubMed ID: 29231157
    [Abstract] [Full Text] [Related]

  • 16. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice.
    Yang H, Yang H, Li Z, Liu L, Wang W, He T, Fan F, Sun Y, Liu J, Li Y, Zeng X.
    Vaccine; 2018 Apr 25; 36(18):2450-2455. PubMed ID: 29580643
    [Abstract] [Full Text] [Related]

  • 17. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, Myers G, Barrett AD, Shope RE, Ratterree M, Chambers TJ, Guirakhoo F.
    Vaccine; 1999 Apr 09; 17(15-16):1869-82. PubMed ID: 10217584
    [Abstract] [Full Text] [Related]

  • 18. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
    Kum DB, Boudewijns R, Ma J, Mishra N, Schols D, Neyts J, Dallmeier K.
    Emerg Microbes Infect; 2020 Apr 09; 9(1):520-533. PubMed ID: 32116148
    [Abstract] [Full Text] [Related]

  • 19. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, Canderan G, Lawson B, Kopycinski J, Graham AS, Rowe DK, Smith MJ, Isern S, Michael S, Silvestri G, Vanderford TH, Castro E, Pantaleo G, Singer J, Gillmour J, Kiwanuka N, Nanvubya A, Schmidt C, Birungi J, Cox J, Haddad EK, Kaleebu P, Fast P, Sekaly RP, Trautmann L, Gaucher D.
    J Clin Invest; 2014 Jul 09; 124(7):3147-58. PubMed ID: 24911151
    [Abstract] [Full Text] [Related]

  • 20. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
    Idoko OT, Domingo C, Tapia MD, Sow SO, Geldmacher C, Saathoff E, Kampmann B.
    Front Immunol; 2020 Jul 09; 11():577751. PubMed ID: 33133096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.